Sotera Health Company (NASDAQ:SHC – Get Free Report) Director Gtcr Investment Xi Llc sold 10,000,000 shares of the business’s stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $15.27, for a total value of $152,700,000.00. Following the completion of the sale, the director owned 12,735,301 shares of the company’s stock, valued at approximately $194,468,046.27. This trade represents a 43.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Sotera Health Price Performance
Sotera Health stock opened at $14.06 on Wednesday. The firm has a market cap of $4.00 billion, a PE ratio of 52.08 and a beta of 1.84. The company has a debt-to-equity ratio of 3.66, a current ratio of 2.46 and a quick ratio of 2.24. The stock’s fifty day moving average price is $17.59 and its two-hundred day moving average price is $16.82. Sotera Health Company has a one year low of $9.53 and a one year high of $19.85.
Sotera Health (NASDAQ:SHC – Get Free Report) last released its earnings results on Tuesday, February 24th. The company reported $0.26 earnings per share for the quarter, beating analysts’ consensus estimates of $0.24 by $0.02. Sotera Health had a return on equity of 42.38% and a net margin of 6.70%.The firm had revenue of $303.44 million during the quarter, compared to the consensus estimate of $300.68 million. During the same period in the prior year, the company posted $0.21 EPS. The company’s revenue was up 4.6% compared to the same quarter last year. Sotera Health has set its FY 2026 guidance at 0.930-1.01 EPS. As a group, research analysts expect that Sotera Health Company will post 0.61 EPS for the current fiscal year.
Hedge Funds Weigh In On Sotera Health
Wall Street Analyst Weigh In
Several equities analysts have commented on the stock. Wells Fargo & Company lowered shares of Sotera Health to an “overweight” rating in a report on Thursday, January 8th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Sotera Health in a research report on Monday, December 29th. Citigroup lifted their price objective on shares of Sotera Health from $21.00 to $23.00 and gave the company a “buy” rating in a research note on Tuesday, February 24th. BMO Capital Markets initiated coverage on shares of Sotera Health in a research report on Thursday, November 13th. They set an “outperform” rating and a $19.00 price objective for the company. Finally, Zacks Research cut Sotera Health from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 30th. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Sotera Health has an average rating of “Moderate Buy” and a consensus price target of $20.43.
Check Out Our Latest Stock Report on Sotera Health
Sotera Health Company Profile
Sotera Health Inc (NASDAQ: SHC) is a global provider of sterilization and laboratory testing services that support the medical device, pharmaceutical, life sciences and consumer product industries. Headquartered in Jacksonville, Florida, the company offers a suite of services designed to ensure products meet rigorous safety and regulatory requirements before reaching market.
Sotera Health operates through three primary service platforms. Its Sterigenics division delivers contract sterilization solutions, including ethylene oxide (EtO), gamma irradiation, electron beam and X-ray technologies.
Featured Articles
- Five stocks we like better than Sotera Health
- The gold chart Wall Street is terrified of…
- What a Former CIA Agent Knows About the Coming Collapse
- Elon Musk already made me a “wealthy man”
- Unlocked: Elon Musk’s Next Big IPO
- 1,500 Banks Just Handed the Fed Your Bank Account
Receive News & Ratings for Sotera Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sotera Health and related companies with MarketBeat.com's FREE daily email newsletter.
